2. Academic Validation
  3. SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer

SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer

  • Med Oncol. 2021 Apr 9;38(5):57. doi: 10.1007/s12032-021-01502-0.
Nianli Liu  # 1 2,  Aoxing Chen  # 3,  Ning Feng  # 3,  Xiaochen Liu 4,  Longzhen Zhang 5 6 7
Affiliations

Affiliations

  • 1 Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. liunli@xzhmu.edu.cn.
  • 2 Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. liunli@xzhmu.edu.cn.
  • 3 Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • 4 Yanzhou District, The Affiliated Hospital of Jining Medical University, Jining, China.
  • 5 Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. jsxyfyzlz1@163.com.
  • 6 Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. jsxyfyzlz1@163.com.
  • 7 Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. jsxyfyzlz1@163.com.
  • # Contributed equally.
PMID: 33835288 DOI: 10.1007/s12032-021-01502-0
Abstract

The small nuclear ribonucleoprotein polypeptides B And B' (SNRPB) is a core component of spliceosome and plays a key role in pre-mRNA splicing. Emerging evidence suggests that it involves in the development of several types of Cancer. Our previous study has demonstrated SNRPB is highly expressed in non-small-cell lung Cancer (NSCLC) and functions as an oncogene. However, whether SNRPB contributes to cisplatin resistance in NSCLC is still unknown. In this study, we found that SNRPB negatively regulates cisplatin resistance in NSCLC cells. Knocking out of SNRPB could significantly decrease cisplatin-induced cell growth inhibition, cell cycle arrest and Apoptosis in H1299 cells. However, enforced expression of SNRPB in H460 cells can markedly promote cisplatin-induced cell growth inhibition, cell cycle arrest and Apoptosis. Our results also indicate that overexpression of SNRPB enhances the inhibitory effects of cisplatin on H460 cell-mediated xenograft tumors. Our results suggest that SNRPB may be a prediction marker for NSCLC patients in response to cisplatin-based chemotherapy.

Keywords

Biomarker; Cisplatin; NSCLC; Resistance; SNRPB.

Figures
Products
Inhibitors & Agonists
Other Products